pipeline

Pipeline

A holistic approach to treating Hirschsprung disease

Neurenati is developing the combination therapy NEU-001 for Hirschsprung disease, as well as diagnostic tools and biomarkers designed to improve the care of patients with Hirschsprung disease, while paving the way for other indications for NEU-001.

PIPELINE

NEU-001 combination therapy

Hirschsprung disease

Inflammatory bowel disease

DISCOVERY
IND-ENABLING
Phase 1

Diagnostic tools for Hirschsprung disease

NEU-CM1: Colonic manometry pre-surgery

DISCOVERY
Phase 0
Q3-2026
Phase 1

Hirschsprung disease biomarkers

NEU-DO1: Diagnostic

NEU-DO2: Disease monitoring

DISCOVERY
CLINICAL VALIDATION